Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bayer Schering Pharma and the National University of Singapore have agreed to co-operate in the field of preclinical cancer research. The initial collaboration will focus on three joint projects in the field of oncology.
Subscribe to our email newsletter
The goal of the joint projects with the National University of Singapore (NUS) is to profile oncology drugs in Asian populations, to identify novel biomarkers and to investigate novel tumor models with high relevance for the clinical situation.
Overall, Bayer is committed to invest up to E10 million in R&D activities in Singapore over the next five to eight years in partnership with Singapore-based universities, hospitals, research institutes and companies.
Andreas Busch, head of global drug discovery and member of the board of Bayer Schering Pharma, said: “This investment in collaboration agreements with scientific institutions in Asia underscores our commitment to develop novel cancer drugs.
“We are looking forward to work together with the experts at the NUS and to make use of Singapore’s translational research capabilities and research infrastructure to develop and further advance new anti-cancer therapies. We also see this agreement as the start of further research collaborations in Singapore that Bayer will continue to invest in.”